PerkinElmer Stock News

Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Revvity, Inc. ( RVTY ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad Singh - CEO, President & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. Thank you.

Revvity, Inc. ( RVTY ) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division Good morning, everybody, and thank you all for joining us for 8 a.m. session with Revvity.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., today announced the launch of new highly-characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium (MDIC) and the National Institute of Standards and Technology (NIST) as part of the Somatic Reference Samples (SRS) Initiative. The Somatic Reference Samples (SRS) Initiative is a public...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals' solutions for bridg...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global H...

Revvity, Inc. operates across two main segments in Life Sciences tools and Diagnostics. Its cloud informatics Signals continue experiencing double-digit growth, while diagnostics in China suffer from macro headwinds. RVTY's latest Q3 2025 revenue figures were up 2% overall. For the most part, US and ex-China growth offsets China's decline.

Revvity, Inc. (NYSE:RVTY ) Q3 2025 Earnings Call October 27, 2025 8:00 AM EDT Company Participants Stephen Willoughby - Senior VP of Investor Relations & Head of ESG Prahlad Singh - CEO, President & Director Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Mi...